Riociguat (Adempas, BAY 63-2521)
Sponsors
Bayer
Conditions
Clinical PharmacologyHIV-DDI
Phase 1
Interaction With HIV Antiretroviral Agents
CompletedNCT02556268
Start: 2016-02-23End: 2016-12-07Updated: 2017-12-06
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
CompletedNCT04364464
Start: 2010-02-19End: 2011-09-20Updated: 2020-04-28
Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight
CompletedNCT04366622
Start: 2010-04-14End: 2011-09-15Updated: 2020-04-29